Showing results (251-260 of 1,750) with videos related to
Sort By:
Pageof 175
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 13, 2017
Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor NivolumabDmitry Tchapyjnikov, Alexandra J BorstJournal of Immunotherapy (Hagerstown, Md. : 1997)|June 13, 2017
Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant TherapyAnet Valdes-Zayas, Zuyen Gonzalez, Vladimir Mulens, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 9, 2010
Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiologyAngela Märten, Markus W Büchler, Wiebke Werft, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2010
Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28Jacalyn Rosenblatt, Zekui Wu, Baldev Vasir, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2017
Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung CancerGiulia C Leonardi, Geoffrey R Oxnard, Andrea Haas, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 19, 2018
Nivolumab Treatment for Cancers in the HIV-infected PopulationElaine Chang, Anita L Sabichi, Jennifer R Kramer, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 1, 2018
Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor ModelFang Zheng, Jianzhong Dang, Hongyu Zhang, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 24, 2016
Radiotherapy to Control Limited Melanoma Progression Following IpilimumabLauren M Kropp, Jennifer F De Los Santos, Svetlana B McKee, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 29, 2017
Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of ImmunotherapyW Kelly Wu, Kristy K Broman, Evan R Brownie, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 2, 2009
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanomaLynn E Spitler, Robert W Weber, Robert E Allen, et al.Pageof 175